BioCardia SVP receives options, RSU tax withholding

BioCardia, Inc. Senior Vice President, Devices Edward M. Gillis received a stock option grant and had shares withheld for taxes in a routine compensation-related filing.

Rhea-AI Filing Summary

BioCardia, Inc. Senior Vice President, Devices Edward M. Gillis received a stock option grant and had shares withheld for taxes in a routine compensation-related filing. He was granted options for 29,442 shares of common stock at an exercise price of $1.20 per share, vesting monthly over four years starting August 6, 2026. In a separate transaction, 17,269 common shares were withheld by BioCardia at $1.24 per share to cover income tax obligations on RSUs that vested June 29, 2026, which the company states does not represent a sale by him. Following these transactions, he directly holds 61,139 stock options and 54,126 common shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider GILLIS EDWARD M

Role Senior Vice President, Devices

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	29,442	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	17,269	$1.24	$21K

Holdings After Transaction: Stock Option (right to buy) — 61,139 contracts (Direct); Common Stock — 54,126 shares (Direct)

Footnotes (2)

1. F1. The reported securities represent the shares that have been withheld by the Issuer to satisfy its income tax, withholding and remittance obligations in connection with the net settlement on July 2, 2026, of the RSUs vested on June 29, 2026 and does not represent a sale by the Reporting Person.
2. F2. The option vests and becomes exercisable as to 1/48th of the shares on August 6, 2026, and each month thereafter, subject to the Reporting Person continuing as a service provider through such date.

Key Figures

Option grant size: 29,442 options Option exercise price: $1.20/share Option expiration: July 6, 2036 +5 more

8 metrics

Option grant size 29,442 options Stock Option (right to buy) granted on July 6, 2026

Option exercise price $1.20/share Exercise price for 29,442 stock options

Option expiration July 6, 2036 Expiration date of granted stock options

Shares withheld for taxes 17,269 shares Withheld on July 2, 2026 for RSU tax obligations

Withholding price $1.24/share Value used for 17,269 withheld common shares

Post-transaction common shares 54,126 shares Direct common stock holdings after tax withholding

Post-transaction options 61,139 options Direct option holdings after option grant

Monthly vesting schedule 1/48th per month Option vests monthly starting August 6, 2026

Key Terms

RSUs, net settlement, Stock Option (right to buy), tax withholding, +1 more

5 terms

RSUs financial

"the net settlement on July 2, 2026, of the RSUs vested on June 29, 2026"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

net settlement financial

"in connection with the net settlement on July 2, 2026, of the RSUs vested"

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

tax withholding financial

"to satisfy its income tax, withholding and remittance obligations"

Tax withholding is the practice of taking a portion of a payment—such as wages, dividends, or sale proceeds—before it reaches the recipient and sending that portion to the tax authority as an advance on the recipient’s eventual tax bill. For investors it matters because withholding reduces immediate cash received and affects after‑tax returns, estimated tax payments, and whether you may owe more or receive a refund when taxes are finally calculated, like having a small automatic savings set aside for your tax bill.

vests and becomes exercisable financial

"The option vests and becomes exercisable as to 1/48th of the shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did BioCardia (BCDA) disclose for Edward M. Gillis?

BioCardia reported that Senior Vice President, Devices Edward M. Gillis received a stock option grant and had shares withheld for taxes. The filing reflects routine compensation activity rather than open-market buying or selling of BioCardia common stock.

How many BioCardia (BCDA) stock options were granted to Edward M. Gillis?

Edward M. Gillis received options for 29,442 shares of BioCardia common stock at a $1.20 exercise price. The options vest in 1/48th increments monthly, beginning August 6, 2026, contingent on his continued service with the company.

Were any BioCardia (BCDA) shares sold by Edward M. Gillis in this Form 4?

The Form 4 states that 17,269 shares were withheld by BioCardia to satisfy tax obligations on vested RSUs. A footnote clarifies this withholding does not represent a sale by Edward M. Gillis in the market or to another party.

What are Edward M. Gillis’s BioCardia (BCDA) holdings after these transactions?

After the reported transactions, Edward M. Gillis directly holds 54,126 shares of BioCardia common stock and 61,139 stock options. These figures come from the post-transaction ownership totals shown for the common stock and option entries in the Form 4.

How do the new BioCardia (BCDA) options for Edward M. Gillis vest?

The filing states the option vests and becomes exercisable as to 1/48th of the shares on August 6, 2026 and monthly thereafter. Vesting requires Edward M. Gillis to continue as a service provider through each applicable vesting date.

Why did BioCardia (BCDA) withhold 17,269 shares from Edward M. Gillis?

BioCardia withheld 17,269 shares to satisfy its income tax, withholding, and remittance obligations from RSUs that vested on June 29, 2026. The company notes this RSU net settlement does not constitute a sale by Edward M. Gillis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 10:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GILLIS EDWARD M

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, Devices

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2026		F		17,269(1)	D	$1.24(1)	54,126	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.2	07/06/2026		A		29,442		(2)	07/06/2036	Common stock	29,442	$0	61,139	D

Explanation of Responses:

1. The reported securities represent the shares that have been withheld by the Issuer to satisfy its income tax, withholding and remittance obligations in connection with the net settlement on July 2, 2026, of the RSUs vested on June 29, 2026 and does not represent a sale by the Reporting Person.

2. The option vests and becomes exercisable as to 1/48th of the shares on August 6, 2026, and each month thereafter, subject to the Reporting Person continuing as a service provider through such date.

	/s/ David McClung, by power of attorney	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)